Tribomechanically activated zeolite (TMAZ) as an adjuvant cancer treatment - Promising results from clinical case observations

被引：0
|
作者：
Ivkovic, S [1 ]
Bendzko, P [1 ]
Schulz, J [1 ]
机构：
[1] Helios Klinikum, Berlin, Germany
来源：
FREE RADICAL BIOLOGY AND MEDICINE | 2004年 / 37卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：S173 / S173
页数：1
相关论文
共 50 条
  • [31] Adjuvant treatment for early epithelial ovarian cancer: Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (P-32)
    Bolis, G
    Colombo, N
    Pecorelli, S
    Torri, V
    Marsoni, S
    Bonazzi, C
    Chiari, S
    Favalli, G
    Mangili, C
    Presti, M
    Zanaboni, F
    Mangioni, C
    ANNALS OF ONCOLOGY, 1995, 6 (09) : 887 - 893
  • [32] Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer:: Results from a nationwide study
    Lundin, J
    Lundin, M
    Holli, K
    Kataja, V
    Elomaa, L
    Pylkkänen, L
    Turpeenniemi-Hujanen, T
    Joensuu, H
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) : 28 - 36
  • [33] Use of red clover in premenopausal breast cancer patients receiving hormonal adjuvant treatment: Biological and clinical implications from a randomized clinical trial
    Ferraris, C.
    Ballestra, B.
    Cappelletti, V.
    Listorti, C.
    Miodini, P.
    Pulice, I.
    Mariani, L.
    Ferrari, E.
    Gambaro, A.
    Maugeri, I.
    Martelli, G.
    Folli, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] Neoadjuvant Versus Adjuvant Treatment of Gastroesophageal Junction Cancer: An Analysis of Data from the Surveillance, Epidemiology, and End Results (SEER) Registry
    Miccio, J. A.
    Oladeru, O. T.
    Xue, Y.
    Yang, J.
    Yoon, H.
    Ryu, S.
    Stessin, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E120 - E120
  • [35] Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
    Andre, T.
    Vernerey, D.
    Im, S. A.
    Bodoky, G.
    Buzzoni, R.
    Reingold, S.
    Rivera, F.
    McKendrick, J.
    Scheithauer, W.
    Ravit, G.
    Fountzilas, G.
    Yong, W. P.
    Isaacs, R.
    Osterlund, P.
    Liang, J. T.
    Creemers, G. J.
    Rakez, M.
    Van Cutsem, E.
    Cunningham, D.
    Tabernero, J.
    de Gramont, A.
    ANNALS OF ONCOLOGY, 2020, 31 (02) : 246 - 256
  • [36] Switching from tamoxifen (TAM) to aromatase inhibitors (AIs) in the adjuvant treatment of breast cancer (BC) patients (pts). Results from the NORA study
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 158 - 158
  • [37] ADJUVANT CHEMOTHERAPY WITH AND WITHOUT TAMOXIFEN IN THE TREATMENT OF PRIMARY BREAST-CANCER - 5-YEAR RESULTS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT TRIAL
    FISHER, B
    REDMOND, C
    BROWN, A
    FISHER, ER
    WOLMARK, N
    BOWMAN, D
    PLOTKIN, D
    WOLTER, J
    BORNSTEIN, R
    LEGAULTPOISSON, S
    SAFFER, EA
    JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (04) : 459 - 471
  • [38] Adjuvant multimodaility treatment in patients with high risk prostate cancer following radical prostatectomy:: Results of a prospective clinical phase-II trial
    Sahi, Dina
    Pfister, David
    Thueer, David
    Ohlmann, Carsten H.
    Heidenreich, Axel
    JOURNAL OF UROLOGY, 2007, 177 (04): : 334 - 334
  • [39] Adjuvant multimodality treatment in patients with high risk prostate cancer following radical prostatectomy:: Results of a prospective clinical phase-II trial
    Sahi, D.
    Pfister, D.
    Ohlmann, C.
    Thueer, D.
    Heidenreich, A.
    ONKOLOGIE, 2008, 31 : 188 - 189
  • [40] Adjuvant multimodality treatment in patients with high risk prostate cancer following radical prostatectomy:: Results of a prospective clinical phase-II trial
    Heidenreich, A.
    Ohlmann, C.
    Pfister, D.
    Thuer, D.
    Engelmann, U. H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 57 - 57
12345